174 related articles for article (PubMed ID: 29345696)
41. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Boccia R; O'Boyle E; Cooper W
BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
[TBL] [Abstract][Full Text] [Related]
43. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.
Celio L; Niger M; Ricchini F; Agustoni F
Core Evid; 2015; 10():75-87. PubMed ID: 26345982
[TBL] [Abstract][Full Text] [Related]
44. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children.
Patil V; Prasada H; Prasad K; Shenoy UV
J Community Support Oncol; 2015 Jun; 13(6):209-13. PubMed ID: 26270519
[TBL] [Abstract][Full Text] [Related]
45. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
47. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
Rigacci L; Landi C; Caruso JP; Puccini B; Alterini R; Carrai V; Perrone T; Bosi A
Leuk Res; 2012 Feb; 36(2):182-5. PubMed ID: 21752467
[TBL] [Abstract][Full Text] [Related]
48. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
49. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
50. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
51. Palonosetron: in the prevention of nausea and vomiting.
Yang LP; Scott LJ
Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
[TBL] [Abstract][Full Text] [Related]
52. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
[TBL] [Abstract][Full Text] [Related]
53. Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - A comparative evaluation.
Gupta K; Singh I; Gupta PK; Chauhan H; Jain M; Rastogi B
Anesth Essays Res; 2014; 8(2):197-201. PubMed ID: 25886226
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.
Zilioli VR; Muzi C; Minga P; Codega P; Crucitti L; Meli E; Esposito A; Panico C; Rusconi C; Cairoli R
Int J Hematol Oncol; 2020 Feb; 9(1):IJH23. PubMed ID: 32382409
[TBL] [Abstract][Full Text] [Related]
55. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
56. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
[TBL] [Abstract][Full Text] [Related]
57. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.
Faria C; Li X; Nagl N; McBride A
Am Health Drug Benefits; 2014 Jan; 7(1):50-8. PubMed ID: 24991390
[TBL] [Abstract][Full Text] [Related]
58. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
[TBL] [Abstract][Full Text] [Related]
60. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
